Growing and managing a small pharma company, whose scientists are developing broad-spectrum antivirals, with planned applications in humans around the world. Using a proprietary process (the VTose® Antiviral Platform), R&D is undertaken in a fully equipped PC-2 (BSL-2) laboratory in Nelson, New Zealand, leveraging Nelson’s internationally-renowned scientific community and global networks.  Kimer Med’s Platform can:Rapidly design and test new antiviral candidates  Customise antivirals to target different types of virus  Reduce drug discovery time (traditionally very slow)  Optimise our antivirals for greater efficacy and safety  Support  both treatment (after infection), and short-term prevention (before infection).  There are around 220 viruses that cause death and disease in humans, but there are only approved antivirals for 11 of them. With no antiviral available for  Dengue, and annual Dengue cases numbering more than 400 million, Kimer Med’s initial development focus is on an antiviral for Dengue. This alone is a NZ$3.8 billion annual opportunity.